Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 2/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.46 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12747029 | 1.00 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL18874981 | 1.00 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL12150955 | 1.00 | LGALS9 (0.46) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL9880215 | 0.96 | LGALS9 (0.45) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL13765953 | 0.89 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL10148629 | 0.88 | NT5E (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL16904875 | 0.87 | LGALS9 (0.45) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL16769133 | 0.87 | LGALS9 (0.48) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL16769153 | 0.87 | LGALS9 (0.48) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA | |
| SCHEMBL12150947 | 0.87 | LGALS9 (0.45) | LGALS9LGALS1LGALS3LGALS7; LGALS7BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064743-A1 | NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2018-03-08 | — | — | US | disclosed |
| US-9821001-B2 | Aminoglycosides and uses thereof in the treatment of genetic disorders | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2017-11-21 | — | — | US | disclosed |
| US-20150352136-A1 | NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352136-A1 | NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | AARS1, NARS1, GOT1 | LGALS9 4229/4885LGALS1 4582/4885LGALS3 4599/4885 |
| US-20180064743-A1 | NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS | AARS1, NARS1, GOT1 | LGALS9 4229/4885LGALS1 4582/4885LGALS3 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.